Unilabs York Bioanalytical Solutions (YBS) has a history of employing
cutting edge technology to maintain its place as Europe’s premier,
independent bioanalytical facility. As part of this commitment to
providing the latest technology to its clients, YBS is pleased to
announce the acquisition of new systems that will help the company
enhance its ability to provide high quality bioanalytical data with
increased efficiency.
Two new Waters Xevo TQ-S LC-MS/MS systems will enable the detection and
quantification of lower levels of conventional small molecule
therapeutics, peptides and oligonucleotides. Linked to Waters Acquity
UPLC systems or Spark Holland’s Symbiosis Pharma automated online solid
phase extraction technology, these systems have proved invaluable in
achieving ground breaking levels of sensitivity, selectivity and
robustness.
Due to the high demand for sensitive peptide assays YBS has added an
additional Spark Holland Symbiosis Pharma, automated online system. The
Symbiosis has been proven to be the technique of choice for peptide and
oligonucleotide analysis. YBS will be presenting how this technology
has revolutionised the analysis of biological therapeutics at several
key scientific meetings this year.
To complement YBS’s other automated techniques, they are pleased to
announce the purchase of a Hamilton Microlab Star Plus robotic system.
This will enhance the analysis of biological samples and will be
utilised for solid phase extraction and protein precipitation assays.
The Hamilton Microlab Star Plus has a proven track record for precision,
accuracy, reliability, flexibility and speed.
Since launch in 1999 and becoming part of the Unilabs group in 2008,
Unilabs York Bioanalytical Solutions has grown to become the largest,
independent provider of bioanalytical services in Europe, offering
pharmaceutical and Biotech companies an unprecedented standard of
service. The company specialises in analysing drug concentrations
(large and small molecules) in body fluids, biomarker analysis and
sample logistics; an essential part of the drug development process.
For further information, please contact David Browne or Jeremy Cook at
Unilabs York Bioanalytical Solutions on 01904 686060, or email your
enquiry to info@yorkbio.com. Further information about Unilabs York
Bioanalytical Solutions can also be obtained from the company’s website
www.yorkbio.com.